Glembatumumab vedotin (GV, CDX-011) is an ADC that contains an antibody that targets glycoprotein non-metastatic b (gpNMB), a transmembrane glycoprotein usually overexpressed in melanoma and other tumors, conjugated to monomethyl auristatin E. A phase II clinical trial using this agent as monotherapy in patients with advanced melanoma is recruiting patients (NCT02302339). The gene discussed is GPNMB; the disease is melanoma.